Michael Hettich

TL;DR: Radiotracers based on therapeutic checkpoint-blocking antibodies permitting sensitive and high-resolution PET imaging of both PD-1 and PD-L1 in immunocompetent mice suggest that T cell responses in the lung, a vital organ continuously exposed to a variety of antigens, are strongly restrained by thePD-1 checkpoint.

TL;DR: In MPN, constitutive JAK2/STAT3/STAT5 activation, mainly in monocytes, megakaryocytes, and platelets, caused PD-L1–mediated immune escape by reducing T cell activation, metabolic activity, and cell cycle progression, which paving the way for immunomodulatory approaches relying on PD-1 inhibition.

TL;DR: FAP– and CD19–4-1BBL thus represent an off-the-shelf combination immunotherapy without requiring genetic modification of effector cells for the treatment of solid and hematological malignancies.

TL;DR: It is found that CD57 was upregulated on activated T cells only upon contact with CD57+ patient-derived GBM-SCs, but not with conventional CD57-negative glioma lines, indicating that this molecule is not a bona fide CSC marker for GBM.

TL;DR: Development of clinically relevant tracers that permit high-sensitivity and high-resolution monitoring of AC133+ glioblastoma stem cells in both subcutaneous and intracerebral xenograft tumors using positron emission tomography and near-infrared fluorescence imaging, two clinically highly relevant imaging modalities are described.